Therapeutic potential of cannabinoids in glaucoma
T Lindner, D Schmidl, L Peschorn, V Pai… - Pharmaceuticals, 2023 - mdpi.com
Glaucoma is a leading cause of irreversible blindness worldwide. To date, intraocular
pressure (IOP) is the only modifiable risk factor in glaucoma treatment, but even in treated …
pressure (IOP) is the only modifiable risk factor in glaucoma treatment, but even in treated …
Cannabinoids in glaucoma patients: The never-ending story
A Passani, C Posarelli, AT Sframeli, L Perciballi… - Journal of clinical …, 2020 - mdpi.com
Glaucoma is one of the principal causes of irreversible blindness worldwide. Yet, intraocular
pressure (IOP) is the main modifiable risk factor for disease progression. In the never-ending …
pressure (IOP) is the main modifiable risk factor for disease progression. In the never-ending …
Cannabinoid applications in glaucoma
S Pinar-Sueiro, R Rodríguez-Puertas… - Archivos de la Sociedad …, 2011 - Elsevier
Introduction Glaucoma is a slowly progressive optic neuropathy that is one of the leading
causes of legal blindness throughout the world. Currently there is a limited group of topical …
causes of legal blindness throughout the world. Currently there is a limited group of topical …
The endocannabinoid system as a therapeutic target in glaucoma
EA Cairns, WH Baldridge, MEM Kelly - Neural plasticity, 2016 - Wiley Online Library
Glaucoma is an irreversible blinding eye disease which produces progressive retinal
ganglion cell (RGC) loss. Intraocular pressure (IOP) is currently the only modifiable risk …
ganglion cell (RGC) loss. Intraocular pressure (IOP) is currently the only modifiable risk …
Cannabinoids in the treatment of glaucoma
T Järvinen, DW Pate, K Laine - Pharmacology & therapeutics, 2002 - Elsevier
The leading cause of irreversible blindness is glaucoma, a disease normally characterized
by the development of ocular hypertension and consequent damage to the optic nerve at its …
by the development of ocular hypertension and consequent damage to the optic nerve at its …
Cannabinoids and glaucoma
I Tomida, RG Pertwee, A Azuara-Blanco - British journal of …, 2004 - bjo.bmj.com
Glaucoma is one of the leading causes of blindness in the world. In spite of the diverse
therapeutic possibilities, new and better treatments for glaucoma are highly desirable …
therapeutic possibilities, new and better treatments for glaucoma are highly desirable …
The arguments for and against cannabinoids application in glaucomatous retinopathy
Glaucoma represents several optic neuropathies leading to irreversible blindness through
progressive retinal ganglion cell (RGC) loss. Reduction of intraocular pressure (IOP) is …
progressive retinal ganglion cell (RGC) loss. Reduction of intraocular pressure (IOP) is …
Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists
BD Hudson, M Beazley, AM Szczesniak… - … of Pharmacology and …, 2011 - ASPET
Intraocular pressure (IOP) is the primary risk factor for glaucoma, a blinding eye disease.
Cannabinoid agonists have long been known to decrease IOP, suggesting they may be …
Cannabinoid agonists have long been known to decrease IOP, suggesting they may be …
Potential roles of (endo) cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
C Nucci, M Bari, A Spanò, MT Corasaniti… - Progress in brain …, 2008 - Elsevier
Recent evidence shows that the endocannabinoid system is involved in the pathogenesis of
numerous neurodegenerative diseases of the central nervous system. Pharmacologic …
numerous neurodegenerative diseases of the central nervous system. Pharmacologic …
Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit
MA Elsohly, EC Harland, DA Benigni… - Current eye …, 1984 - Taylor & Francis
Thirty-two different cannabinoids were tested for their ability to reduce intraocular pressure
(IOP) in the rabbit. These included many of Δ9-and Δ8-THC derivatives and metabolites …
(IOP) in the rabbit. These included many of Δ9-and Δ8-THC derivatives and metabolites …